当前位置: 首页 > 期刊 > 《糖尿病新世界》 > 2017年第18期
编号:13220352
二甲双胍对胰岛素抵抗患者甲状腺体积及结节的影响(3)
http://www.100md.com 2017年9月15日 糖尿病新世界 2017年第18期
     [7] Ittermann T, Markus MR, Schipf S, et al.Metformin inhibits goitrogenous effects of type 2 diabetes[J].European Journal of Endocrinology,2013,169(1):9-15.

    [8] Ogbera AO, Kuku S, Dada O,et al.The metabolic syndrome in thyroid disease: a report from Nigeria[J].Indian Journal of Endocrinology and Metabolism,2012,16(3):417-422.

    [9] SantistebanP,Acebron A, Polycarpou-Schwarz M, et al.Insulin and insulin-like growth factor I regulate a thyroid-specific nuclear protein that binds to the thyroglobulin promoter[J].Molecular Endocrinology,1992(6):1310-1317.

    [10] Díez JJ,Iglesias P.Relationship between serum thyrotropin concentrations and metformin therapy in euthyroid patients with type 2 diabetes[J].Clinical Endocrinology,2013,78(4):505-511.

    [11] Chen G, Xu S, Renko K,et al. Metformin inhibits growth of thyroid carcinoma cells, suppresses self-renewal of derived cancer stem cells, and potentiates the effect of chemotherapeutic agents[J].Journal of Clinical Endocrinology and Metabolism,2012,97(4):510-520.

    [12] Rezzonico J,Rezzonico M,Pusiol E,et al.Metformin treatment for small benign thyroid nodules in patients with insulin resistance[J].Metabolic Syndrome and Related Disorders,2011, 9(1): 69-75., http://www.100md.com(张楠)
上一页1 2 3